Skip to main content

Advertisement

SpringerLink
Log in

Pembrolizumab plus enfortumab vedotin in urothelial cancer

  • Clinical Outlook
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion. This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Powles, T. B. et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34 (Suppl. 2), S1340 (2023).

    Article  Google Scholar 

  2. Chikuma, S. et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell energy? in vivo. J. Immunol. 182, 6682–6689 (2009).

    Article  CAS  PubMed  Google Scholar 

  3. Milella, M. et al. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. Br. J. Cancer 79, 770–779 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sakatani, T. et al. IFN-gamma expression in the tumor microenvironment and CD8-positive tumor-infiltrating lymphocytes as prognostic markers in urothelial cancer patients receiving pembrolizumab. Cancers 14, 263 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Baker, S. C. et al. The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy. Cancers 14, 5295 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Liu, Y. et al. Role of nectin-4 protein in cancer (Review). Int. J. Oncol. 59, 93 (2021).

    Article  CAS  PubMed  Google Scholar 

  7. Chen, Z. et al. Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers. Front. Cell Dev. Biol. 9, 808208 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Challita-Eid, P. M. et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 76, 3003–3013 (2016).

    Article  CAS  PubMed  Google Scholar 

  9. Gray, E. et al. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. J. Immunother. Cancer 11, e007572 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ganguli, N., Kumari, P., Dash, S. & Samanta, D. Molecular and structural basis of TIGIT: nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy. Biochem. Biophys. Res. Commun. 677, 31–37 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Unit, Macerata Hospital, Macerata, Italy

    Matteo Santoni

  2. Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Hideki Takeshita

  3. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    Francesco Massari & Veronica Mollica

  4. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy

    Francesco Massari & Veronica Mollica

  5. 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

    Aristotelis Bamias

  6. Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy

    Linda Cerbone

  7. Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic

    Ondrej Fiala

  8. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

    Ondrej Fiala

  9. Medical Oncology Unit, University Hospital of Parma – Department of Medicin and Surgery, University of Parma, Parma, Italy

    Sebastiano Buti

  10. Department of Molecular Medicine, Sapienza University, Rome Italian Pasteur Institute, Cenci-Bolognetti Foundation, Rome, Italy

    Angela Santoni

  11. Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Joaquim Bellmunt

Authors
  1. Matteo Santoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideki Takeshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Massari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aristotelis Bamias
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Linda Cerbone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ondrej Fiala
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Veronica Mollica
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sebastiano Buti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Angela Santoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Joaquim Bellmunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.S., F.M. and J.B. researched data for the article. All authors contributed substantially to discussion of the content. M.S. wrote the article. All authors reviewed and edited the manuscript before submission.

Corresponding author

Correspondence to Francesco Massari.

Ethics declarations

Competing interests

M.S. has received research support and honoraria from Janssen, Bristol Myers Squibb, Ipsen, MSD, Astellas and Bayer, all unrelated to the present paper. F.M. has received research support and/or honoraria from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, BMS, Janssen, Ipsen, MSD and Pfizer outside the submitted work. L.C. has received honoraria for advisory boards, speaker engagements and scientific consultancy for educational purposes from AstraZeneca, EISAI, MSD, Ipsen, BMS and A.A.A., and is a past MSD employee in Medical Affairs. O.F. received honoraria from Novartis, Janssen, Merck and Pfizer for consultations and lectures unrelated to this project. S.B. has received honoraria for speaking at scientific events and advisory roles from AstraZeneca, Bristol Myers Squibb, Ipsen, Merck, Eisai, MSD, Novartis and Pfizer, and research funding from Novartis and Pfizer. J.B. reports institutional and personal, paid and unpaid support for research, advisory boards, consultancy and honoraria (all outside this work) from AstraZeneca, Bristol Myers-Squibb, EMD Serono, Merck, Pfizer, Roche, Sanofi/Aventis, Up-To-Date and CME events (Peerview, OncLive), outside the submitted work; no speaker’s bureau. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Santoni, M., Takeshita, H., Massari, F. et al. Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00858-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41585-024-00858-y

  • Springer Nature Limited

Search

Navigation